Bronnen:
- Palandri F, Tiribelli M, Benevolo G, et al. Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study. Hematol Oncol. 2017 May 17.,Verstovsek S, Mesa RA, Gotlib J, et al. A double‐blind, placebocontrolled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799‐807.,Harrison C, Kiladjian JJ, Al‐Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787‐98.